HER-2能作为预后指标吗?——HER-2与转移性结直肠癌(三)

2017-08-04 佚名 肿瘤资讯

HER-2能作为预后指标吗?——HER-2与转移性结直肠癌(三)

结直肠癌的HER2检测:

2015年意大利 Silvia Marsoni 和 Marcello Gambacorta等学者,建立了一个针对于结直肠癌中HER2表达的特异性的评价标准 (HERACLES Diagnostic Criteria)。评价标准的建立分两步。首先他们组建了一个病理学家共识小组,利用既往乳腺癌胃癌的HER2检测标准,结合大肠癌的组织特异性,对256例大肠癌患者进行HER2检测,建立结直肠癌的HER2检测标准;随后,他们利用建立的结直肠癌HER2检测标准,对830例KRAS 12/13 wild-type mCRC进行印证。最终确立了HER2结直肠癌诊断的专家共识。其与胃癌和乳腺癌诊断的差异点主要在两部分。第一是表达位置,由于大肠癌不同于胃癌和乳腺癌的腺体形态,专家组认为,只有在细胞外周、基底和侧壁的细胞膜表达才是有意义的HER2阳性表达;其次是进行FISH(荧光原位杂交)检测的标准,我们都知道HER2 2+需要进行FISH检测,但在结直肠癌中,几乎所有HER2 2+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER2 2+且在大于50%的细胞中表达,才有必要进行FISH检测。


HER2表达与预后

之前我们的研究显示,HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何呢。韩国的两项单中心研究可能会给我们答案。

其中一项研究,纳入了2003-2013年142例RAS野生、抗EGFR治疗失败的mCRC患者,检测标准就是刚刚我们提到的HERACLES Diagnostic Criteria。结果发现,HER2阳性表达率为5%( 7/142)。长期生存显示,HER2阳性表达患者,PFS显着较差,OS较差但没有显着差异。

另外一项研究纳入了2003-2009年191例mCRC患者,其中KRAS野生94例(49.2%),此外研究还检测了每个患者的HER2, BRAF and PIK3CA状态 (RT-PCR)。研究结果显示,无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。

HER2表达与原发灶肿瘤位置

接下来我们来看一下HER2表达与原发肿瘤位置的关系,多项研究显示,HER2高表达在直肠和远端结肠患者中更常见。在HERACLES研究中,85%的HER2阳性患者患者原发灶位于远端结肠或者直肠。在另外一项韩国的研究中,HER2阳性11例,其中9例位于直肠。此外,根据HERACLES研究的结果,HER2在原发灶和转移灶中的表达情况基本一致。没有必要针对转移灶进行重新活检。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-10-08 jyzxjiangqin

    结直肠癌的治疗.

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-06 zhu_jun9840
  6. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-05 随梦飞扬

    HER2在原发灶和转移灶中的表达情况基本一致

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-05 随梦飞扬

    HER2高表达在直肠和远端结肠患者中更常见

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-05 随梦飞扬

    HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-05 随梦飞扬

    无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=251267, encodeId=06a125126eca, content=结直肠癌的治疗., beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Oct 08 07:23:58 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1374168, encodeId=469e13e4168ff, content=<a href='/topic/show?id=8de610018644' target=_blank style='color:#2F92EE;'>#预后指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100186, encryptionId=8de610018644, topicName=预后指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca3c375, createdName=jwf_2001, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386265, encodeId=68431386265ae, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452948, encodeId=1b581452948bd, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495798, encodeId=bf331495e982f, content=<a href='/topic/show?id=27eb8e1381' target=_blank style='color:#2F92EE;'>#HER-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8713, encryptionId=27eb8e1381, topicName=HER-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6b8b9208832, createdName=zhu_jun9840, createdTime=Sun Aug 06 01:49:00 CST 2017, time=2017-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230288, encodeId=61b823028846, content=HER2在原发灶和转移灶中的表达情况基本一致, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:22 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230287, encodeId=7e3f23028ee5, content=HER2高表达在直肠和远端结肠患者中更常见, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:57:05 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230286, encodeId=c0be2302866b, content=HER2表达与抗EGFR治疗的效果显着相关。那么HER2与mCRC患者预后的关系如何, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:30 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230285, encodeId=57cf2302859b, content=无论是在全部患者中,还是在未接受抗EGFR治疗的患者中,HER2扩增突变或者BRAF突变的患者,其生存最差;KRAS突变患者其次;生存最好的是KRAS野生且不伴有BRAF突变和HER2扩增的患者。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:56:07 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=230284, encodeId=bbfe230284d0, content=结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Sat Aug 05 08:54:17 CST 2017, time=2017-08-05, status=1, ipAttribution=)]
    2017-08-05 随梦飞扬

    结直肠癌中,几乎所有HER22+且在小于50%的细胞中表达的患者,均为FISH(-),实际上没有必要进行FISH的检测;只有HER22+且在大于50%的细胞中表达,才有必要进行FISH检测。

    0

相关资讯

ASCO 2017:欧美权威专家访谈集锦:Her-2扩增检测为mCRC末线治疗方案提供线索

表皮生长因子受体2(Her-2)是表皮生长因子受体家族的一名重要成员,对细胞生长、分化、凋亡的调节起着重要作用。近年来,随着靶向治疗在肠癌领域的不断发展,临床医生开始更加重视对患者的治疗结果的预测,并选择个体化的治疗方案。正因为如此,Her-2在转移性结直肠癌(mCRC)诊疗中过程中扮演的角色愈加受到关注。在2017年美国临床肿瘤学会(ASCO)年会现场,多名欧美肠癌领域权威专家接受了记者采访,对

Ann Oncol:HER-2靶向治疗方案对胃癌有效

胃癌是世界上致死率第二高的癌症,并且其治疗管理,特别是对于晚期患者的管理近年来进展甚微。尤其是迄今为止还没有一种靶向治疗的用药模型整合入治疗方案备选选项。HER2过表达越来越被认为是一种频繁发生的分子异常现象,在乳腺癌中受基因扩增的驱动。越来越多的证据证实HER2过表达在胃癌发生发展中起作用,它还与预后差和浸润性强等特征紧密相关。此外,体外和体内胃癌模型的临床前数据显示抗HER2治疗有显著性的抗肿

Lancet Oncol:希腊神话中的HERACLES为结直肠癌的精准治疗助一臂之力——HER-2与转移性结直肠癌(一)

HER-2(Human epidermal growth factor receptor 2 gene ERBB2) 是ERBB家族的成员,我们常说的EGFR也是其中的成员之一。HER-2基因定位于染色体17q12-21.32上,编码相对分子质量为185000的跨膜受体样蛋白,具有酪氨酸激酶活性。HER-2在乳腺癌、胃癌中表达率较高,目前已经成为这两种肿瘤有效的治疗靶点。当受到外界刺激时,HER-

HER-2与抗-EGFR治疗——HER-2与转移性结直肠癌(二)

HER-2与抗-EGFR治疗——HER-2与转移性结直肠癌(二)

Breast :乳腺癌的免疫预防疫苗或将问世

一项来自意大利博洛尼亚大学的最新研究显示,在小鼠实验模型上已成功研发了针对乳腺癌进行免疫预防的有效抑制疫苗。该临床前期结果为人类癌症免疫预防基因表达提供了有效参考,同时预示该疫苗可成功实现人类基因表达,属于肿瘤免疫治疗的阶梯形进步。 肿瘤免疫预防可在健康个体中加强免疫防御,并可有效控制肿瘤发病。在以往的研究中,病毒性肿瘤的预防已在人类肝癌